This educational session will discuss advances in how relapsed/refractory CLL patients and those who fail a treatment are treated today.6 December 2022 – CLLAN Webinar on “CLL treatment in the relapsed-refractory setting and promising therapeutic approaches to fulfil unmet needs”
19:00 – 20:30 CET / 18:00 – 19:30 GMT / 10:00 – 11:30 PST
Link for registration
Should be excellent. Proud to be part of the team.
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLLCalling all treated with Venetoclax/Venclexa/ABT-199 - and all others interested in supporting Australians to gain non-chemo CLL treatmentIs It Time to Treat Your CLL? What You Need to KnowUK Zoom meeting - COVID-19 and shielding update for UK CLL Patients
